Organon & Co. (NYSE:OGN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Organon & Co. (NYSE:OGN) have received a consensus rating of “Hold” from the seven brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $20.80.

A number of equities analysts recently weighed in on OGN shares. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Morgan Stanley decreased their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, Barclays decreased their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday.

Organon & Co. Stock Down 4.0 %

OGN traded down $0.66 during trading on Friday, reaching $15.66. 1,196,459 shares of the stock were exchanged, compared to its average volume of 2,715,229. The stock has a market cap of $4.03 billion, a P/E ratio of 3.11, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The stock’s 50 day moving average price is $15.34 and its two-hundred day moving average price is $17.53. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. Equities analysts expect that Organon & Co. will post 3.82 EPS for the current year.

Institutional Investors Weigh In On Organon & Co.

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Organon & Co. by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock worth $453,593,000 after buying an additional 218,165 shares in the last quarter. Pacer Advisors Inc. grew its stake in Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after buying an additional 11,140,388 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Organon & Co. by 1.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company’s stock worth $147,634,000 after buying an additional 136,760 shares in the last quarter. LSV Asset Management grew its stake in Organon & Co. by 0.4% during the fourth quarter. LSV Asset Management now owns 7,525,076 shares of the company’s stock worth $112,274,000 after buying an additional 30,557 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Organon & Co. by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 4,260,218 shares of the company’s stock worth $63,582,000 after buying an additional 12,110 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.